Semaglutide: Double-edged Sword with Risks and Benefits
Семаглутид: палка о двух концах — риски и преимущества
2025-01-01
SCID: 54.1/ry27wc2e
Discuss with AI
Adverse effectsCardiovascular risk reductionGlycemic controlSemaglutideType 2 diabetes mellitus
Figures from the paper
Abstract (AI)
Type 2 Diabetes Mellitus therapy has evolved over the years to now include a new class of therapeutics, semaglutide. This article reviews the mechanism of action and formulation of semaglutide therapy, potential benefits, contraindications, adverse effects, and drug interactions. Oral and subcutaneous semaglutide therapies have shown effectiveness in improving glycemic control, weight loss, and reducing cardiovascular risks associated with diabetes mellitus. Semaglutide has also shown potential in being used as a therapeutic strategy in Alzheimer's disease due to its anti-neuroinflammatory effects and being used to treat polycystic ovary syndrome. However, semaglutide therapy is also associated with concerning adverse effects like acute pancreatitis, anesthetic risks like pulmonary aspiration or residual gastric content, acute kidney injury, acute gallbladder injury, nonarteritic anterior ischemic optic neuropathy and diabetic retinopathy. Contraindications of semaglutide include history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and pregnancy. Drug interactions to consider with semaglutide therapy include those also used in diabetes treatment, like metformin, as well as anti-psychotics, due to anti-psychotics associated weight gain. The findings of this article emphasize the need for a cross-disciplinary approach to understand the molecular mechanisms and clinical implications of semaglutide on patients with complex medical histories and treatment regimens. The potential anesthetic risks of semaglutide therapy warrant careful consideratiion with ethical concerns. Further studies can assess if there is a need to modify pre-operative guidelines to account for patient using semaglutide and how delayed gastric emptying and constitpation will affect surgical outcomes and complications. While semaglutide therapy for diabetes mellitus has been established, there is a need for extensive research on repurposing semaglutide in neurodegenerative disease treatment.
Key Findings
1
Reported or concerning adverse effects include acute pancreatitis, pulmonary aspiration or residual gastric content during anesthesia, acute kidney injury, gallbladder injury, nonarteritic anterior ischemic optic neuropathy, and diabetic retinopathy.
2
Semaglutide is contraindicated in patients with medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and during pregnancy.
3
Semaglutide, administered orally or subcutaneously, improves glycemic control, promotes weight loss, and reduces cardiovascular risks in diabetes mellitus.
4
Semaglutide’s delayed gastric emptying and constipation may require modified preoperative guidance, while further research is needed to evaluate surgical risks and therapeutic repurposing.
5
The review identifies potential repurposing of semaglutide for Alzheimer’s disease through anti-neuroinflammatory effects and for polycystic ovary syndrome.
Research Object
Semaglutide therapy in patients with type 2 diabetes mellitus and related or potential comorbid indications
Research Subject
Semaglutide’s mechanisms, formulation, therapeutic benefits, contraindications, adverse effects, drug interactions, and perioperative risks
Publication Details
Publication Date
2025-01-01
Journal
Publisher
ISSN
Cited by
37
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest